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ABSTRACT
Long-lived multipotent stem cells (ISCs) at the base of intestinal crypts adjust
their phenotypes to accommodate normal maintenance and post-injury regeneration
of the epithelium. Their long life, lineage plasticity, and proliferative potential
underlie the necessity for tight homeostatic regulation of the ISC compartment.
In that context, the guanylate cyclase C (GUCY2C) receptor and its paracrine
ligands regulate intestinal epithelial homeostasis, including proliferation, lineage
commitment, and DNA damage repair. However, a role for this axis in maintaining
ISCs remains unknown. Transgenic mice enabling analysis of ISCs (Lgr5-GFP) in the
context of GUCY2C elimination (Gucy2c–/–) were combined with immunodetection
techniques and pharmacological treatments to define the role of the GUCY2C signaling
axis in supporting ISCs. ISCs were reduced in Gucy2c–/– mice, associated with loss
of active Lgr5+ cells but a reciprocal increase in reserve Bmi1+ cells. GUCY2C was
expressed in crypt base Lgr5+ cells in which it mediates canonical cyclic (c) GMPdependent signaling. Endoplasmic reticulum (ER) stress, typically absent from ISCs,
was elevated throughout the crypt base in Gucy2c–/– mice. The chemical chaperone
tauroursodeoxycholic acid resolved this ER stress and restored the balance of ISCs,
an effect mimicked by the GUCY2C effector 8Br-cGMP. Reduced ISCs in Gucy2c–/–mice
was associated with greater epithelial injury and impaired regeneration following
sub-lethal doses of irradiation. These observations suggest that GUCY2C provides
homeostatic signals that modulate ER stress and cell vulnerability as part of the
machinery contributing to the integrity of ISCs.

INTRODUCTION

turnover, intestinal insults, such as inflammation, oxidative
damage, and radiation [4, 5] induce cell death, requiring
replacement to maintain the epithelial barrier. These
processes of turnover and regeneration are driven by an
equally dynamic population of intestinal stem cells (ISCs)
whose characteristics are only beginning to emerge [2].
The highly organized ISC compartment at the
base of crypts contains cell types with distinct marker
expression and functional phenotypes. Lgr5+, or crypt
base columnar (CBC), cells are long-lived multipotent
stem cells located at crypt cell positions 0–4 that

The intestinal epithelium is highly dynamic,
undergoing continuous cycles of renewal and repair. Stem
cells at the base of crypts give rise to progenitor cells that
continue to divide, migrate up the crypt-villus axis, and
differentiate into the specialized epithelial cell types of
the intestine [1]. Absorptive cells are sloughed off into the
intestinal lumen in a conveyor belt fashion on a weekly
basis, while secretory cells such as tuft cells and Paneth
cells survive for weeks [2, 3]. Beyond this programmed
www.impactjournals.com/oncotarget
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Lgr5-EGFP-IRES-CreERT2 mice in which GUCY2C was
eliminated (Lgr5-EGFP-Cre-Gucy2c–/–; Supplementary
Figure 1 and Figure 1D), confirmed by immunofluorescence
microscopy (Figure 1E–1F and Supplementary Figure
2). Moreover, lineage tracing in Lgr5-EGFP-CreGucy2c+/+ and –Gucy2c–/– mice crossed onto the RosaSTOPfl-LacZ background revealed that Gucy2c–/– mice
had fewer LacZ-labeled crypts (Figure 1G–1H).
Conversely, Gucy2c–/– mice exhibited an expanded
population of Bmi1+ cells by immunofluorescence
microscopy (Figure 1I–1J and Supplementary Figure 3)
which was confirmed by immunoblot analysis (Figure
1K–1L). Together, these results suggest that eliminating
GUCY2C signaling rebalances stem cell populations,
favoring a “reserve” ISC phenotype.

divide daily to drive weekly turnover of the epithelium,
making them the “active” stem cells [6]. These cells are
exquisitely sensitive to insult and are intimately associated
with differentiated cells that supply essential regulatory
signals, including Paneth cells [6-8]. Another long-lived,
multipotent stem cell type located higher up the crypt
axis around cell positions 4–8 commonly expresses the
marker Bmi1 [9]. These Bmi1+ cells are quiescent and
contribute minimally to tissue homeostasis [6]. However,
upon injury, Bmi1+ cells can restore both the more active
CBCs as well as all of the differentiated cell types of the
intestinal epithelium, earning them the label of “reserve”
ISC [6, 10]. Despite the sensitivity of Lgr5+ cells to death
upon intestinal insult and the contribution of Bmi1+ cells
to regeneration, Lgr5+ cells are required for recovery from
radiation-induced gastrointestinal damage [5]. While the
identity and function of intestinal stem cell populations are
emerging, mechanisms contributing to their maintenance
and relative balance continue to be refined [6-8, 11].
GUCY2C is a membrane-associated guanylate
cyclase receptor selectively expressed in apical membranes
of intestinal epithelial cells from the duodenum to the
distal rectum [12]. Cognate ligands are structurally similar
peptides and include the paracrine hormones guanylin,
produced throughout the intestine, and uroguanylin,
produced selectively in small intestine, and the heat-stable
enterotoxins (STs) produced by diarrheagenic bacteria
[12]. GUCY2C originally was identified as a mediator of
intestinal fluid and electrolyte secretion contributing to the
pathophysiology of enterotoxigenic diarrhea [12]. However,
the GUCY2C-paracrine hormone axis has emerged as an
essential regulator of key homeostatic processes, including
cell proliferation [13, 14], lineage commitment [15], and
DNA damage repair [14], functions that are essential to
the integrity of the crypt [16]. Further, in murine models
of tumorigenesis or inflammatory bowel disease, in which
injury and recovery characteristically involve ISCs [17],
silencing GUCY2C amplifies pathophysiology, tissue
damage, and mortality [14, 18–21]. Here, we explore the
role for GUCY2C signaling in maintaining ISCs.

Functional expression of the GUCY2C signaling
axis in ISCs
Lgr5+GFP+ cells were collected by FACS from
Lgr5-EGFP-Cre-Gucy2c+/+
and
–Gucy2c–/– mice
(Supplementary Figure 4) [23] and enrichment verified by
RT-qPCR of stem (Lgr5) and differentiated cell [sucrose
isomaltase (SI)] mRNA markers (Figure 2A). Expression
of Gucy2c mRNA in stem (Lgr5High/SILow) cells was
quantitatively similar to that of differentiated (Lgr5Low/
SIHigh) cells suggesting similar levels of expression in
stem cell and differentiated compartments (Figure 2B).
Immunofluorescence microscopy confirmed specific
co-localization of GUCY2C in Lgr5+GFP+ stem cells
(Figure 2C and Supplementary Figure 5). To confirm
functionality of the GUCY2C receptor in ISCs, ST was
injected into segments of intestinal lumen of Lgr5-EGFPCre-Gucy2c+/+ and Lgr5-EGFP-Cre-Gucy2c–/– mice [24].
Luminal exposure to this GUCY2C agonist [25] produced
cGMP accumulation and cGMP-specific phosphorylation
of the downstream target of cGMP-dependent protein
kinase, vasodilator-stimulated phosphoprotein (VASP), in
Lgr5+GFP+ cells, in Gucy2c+/+, but not in Gucy2c–/–, mice
(Figure 2D) highlighting the functionality of GUCY2C
in ISCs. Further, 8Br-cGMP, a cell-permeable analog of
the GUCY2C second messenger cGMP [26], restored the
balance of ISCs, returning Lgr5+GFP+ (Figure 2E) and
Bmi1+ (Figure 2F) cells in Gucy2c–/– mice to levels that
were comparable to those in Gucy2c+/+ mice. Moreover,
the oral GUCY2C agonist linaclotide (Linzess™,
Ironwood, Cambridge, MA) amplified the efficiency of
enteroid formation in Gucy2c+/+ mice (Figure 2G). These
observations reinforce the role of GUCY2C signaling in
maintaining ISCs.

RESULTS
Eliminating GUCY2C expression disrupts ISC
numbers
Stem cells were enumerated in small intestinal
crypts from Gucy2c+/+ and Gucy2c–/– mice by electron
microscopy. Wedge-shaped cells in crypt positions
0 to 5 were included, and Paneth cells were excluded by
their vesicular morphology (Figure 1A) [6–8]. The total
number of ISCs in the crypt base was reduced in the absence
of GUCY2C (Figure 1B). Similarly, ex vivo enteroid
formation, a measure of ISC number and function [22],
was reduced in the absence of GUCY2C ( p < 0.001; Figure
1C). FACS analyses revealed fewer Lgr5+/GFPHigh cells in
www.impactjournals.com/oncotarget

GUCY2C signaling opposes crypt ER stress
The normal ISC compartment minimizes endoplasmic
reticulum (ER) stress, and prolonged exposure induces
ISCs to shift from the stem cell compartment into the
102924

Oncotarget

proliferating progenitor cell pool [27, 28], an effect which
is phenocopied by eliminating GUCY2C signaling [13–15,
20, 29]. Here, elimination of GUCY2C expression induced
over-expression of the chaperone protein BiP (Grp78), a
canonical marker of ER stress [30], in crypts in Gucy2c–/–
mice (Figure 3A–3D). Interestingly, markers of the unfolded
protein response induced by ER stress, including ATF6,
calreticulin, and phosphorylated eIF2α (p-eIF2α), were
unchanged in those crypts [31] (Figure 3A, 3B). Moreover,
the pro-apoptotic protein CHOP, which eliminates cells
with irreversible ER stress [32], was paradoxically reduced
in those crypts (Figure 3A, 3B). This pattern of markers
specifically reflects adaptive ER stress, in which chaperones
like BiP are over-expressed to relieve chronic ER stress,
minimizing the unfolded protein response, while CHOP
transcription is down-regulated to prevent cell death [33, 34].
In that context, tauroursodeoxycholic acid (TUDCA), a
bile salt that mimics the chaperone protein BiP to reduce
ER stress by relieving protein misfolding [35], restored
normal BiP expression in crypts in Gucy2c–/– mice, an
effect which was mimicked by 8Br-cGMP (Figure 3C–3D).
Moreover, like 8Br-cGMP (Figure 2F–2G), TUDCA also
restored Lgr5+GFP+ (Figure 3E) and Bmi1+ (Figure 3F)
cells to normal levels in Gucy2c–/– mice. These observations

underscore the role of GUCY2C signaling in opposing ER
stress that is essential to maintaining ISCs.

GUCY2C maintains ISCs supporting
regeneration after radiation injury
Intestinal irradiation is an established model to
quantify ISC vulnerability and regenerative capacity [36].
Lgr5+ cells are exquisitely sensitive to, and depleted by,
irradiation while Bmi1+ cells are recruited to expand and
repopulate the crypt base to support regeneration [6]. A
single sub-lethal 10 Gy dose of whole-body radiation
produced massive crypt death quantified by the microcolony
assay [37] in small intestines of Gucy2c+/+ and Gucy2c–/–
mice (Figure 4A). However, Gucy2c–/– mice displayed
greater fractional crypt loss compared to Gucy2c+/+ mice
48 hours after irradiation (36% vs 62%, p < 0.05), consistent
with increased susceptibility to radiation-induced ISC cell
death in the absence of GUCY2C signaling (Figure 4A).
Further, the absence of GUCY2C signaling was associated
with a regenerative lag; Gucy2c–/– mice recovered only
49% of their crypts compared to 82% in Gucy2c+/+ mice at
72 hours ( p < 0.01), consistent with enhanced vulnerability
of the crypt in the absence of GUCY2C (Figure 4A–4B).

Figure 1: Gucy2c maintains the balance of Lgr5+ and Bmi1+ cells in crypts. (A–B) Enumeration of CBC ISCs in small
intestinal sections using transmission electron microscopy (n = 3 mice, >30 crypts/mouse). (C) Ex vivo enteroid forming capacity of
crypts from Gucy2c–/– mice relative to Gucy2c+/+ mice. (D) Quantification of Lgr5+ (GFPHigh) cells by flow cytometry in crypts from Lgr5EGFP-Cre-Gucy2c+/+ and Gucy2c–/– mice. (E–F) Enumeration of Lgr5+GFP+ cells in intestinal crypts by EGFP IF (>4 sections/mouse).
(G–H) Crypt Lgr5+ cell lineage tracing events expressed as a percent of total crypts per section (>4 sections/mouse). (I–J) Bmi1+ cells
per intestinal section (>4 sections/mouse). (K–L) Quantification of Bmi1 expressed in isolated crypt lysates, relative to β-actin (n = 5
Gucy2c+/+, 4 Gucy2c–/–). *p < 0.05; ***p < 0.001. Bars in E and G represent 50 µm; bar in I represents 20 µm.
www.impactjournals.com/oncotarget
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Indeed, the absolute number of Lgr5+GFP+ cells 48 hours
after irradiation was lower (31 vs 9, p < 0.05) in Gucy2c–/–,
compared to Gucy2c+/+, mice (Figure 4C). In contrast,
Bmi1+ cells expanded to repopulate the crypt after radiation
in Gucy2c+/+ mice, achieving a maximum response at
48 h, while in Gucy2c–/– mice there was a paradoxical loss
of those cells, without recovery, (p < 0.01; Figure 4D),
paralleling the regenerative lag (Figure 4A). Together,

these observations support the hypothesis that GUCY2C
signaling, at least in part, protects Lgr5+ and Bmi1+ stem
cells required for regenerative responses to radiation injury.

DISCUSSION
An emerging paradigm suggests that the crypt
harbors populations of multi-potent stem cells which

Figure 2: Functional GUCY2C is expressed in Lgr5+ cells. (A) Flow sorting of GFP+ and GFP– cells from crypts of Lgr5-EGFPCre-Gucy2c+/+ mice produced populations of active stem (Lgr5High/SILow) and differentiated (Lgr5Low/SIHigh) cells (n = 3). (B) GUCY2C mRNA
expression, quantified by RT-PCR, was compared in Lgr5High/SILow and Lgr5Low/SIHigh cells. (C) GUCY2C (green), immunofluorescence in
GFP+ (red) cells. β-catenin (cyan) highlights individual cells and DAPI (blue) highlights nuclei. (D) ST activates GUCY2C and downstream
VASP serine 239 phosphorylation (P-VASP-239) (white) in GFP+ (green) cells in Gucy2c+/+, but not Gucy2c–/–, mice. β-catenin (red)
highlights individual cells and DAPI (blue) highlights nuclei. (E–F) 8Br-cGMP reconstitutes levels of (E) Lgr5+GFP+ and (F) Bmi1+ cells
in crypts of Gucy2c–/– mice that are comparable to those in Gucy2c+/+ mice. (G) Linaclotide enhances the enteroid-forming capacity of
crypts in Gucy2c–/– mice relative to Gucy2c+/+ mice. *p < 0.05; ns, not significant. Bar in C represents 50 µm; bar in D represents 20 µm.

www.impactjournals.com/oncotarget
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support the unique homeostatic requirements of the
continuously regenerating intestinal epithelium.
While several intestinal stem cell populations have
been suggested, reflecting phenotypic and functional
characteristics, there is consensus on two broad categories
[38]. Active crypt base stem cells at position 0-4 which are
rapidly proliferating and sensitive to insults like radiation
are the source of transit amplifying cells which ultimately
replace differentiated epithelial cells in routine mucosal
maintenance [6, 39]. In contrast, stem cells residing at
positions above 4, which are slowly proliferating and
relatively resistant to insults, comprise a reserve population
that regenerates the intestinal epithelium following injury
[40]. While several protein markers have been purported
to identify discreet stem cell populations, all are variably
expressed by ISCs in crypts [41]. However, Lgr5 and
Bmi1 appear to be relatively selective as markers of
active and reserve stem cell populations, respectively [38].

This heterogeneity in marker expression likely reflects
the plasticity of ISCs. Indeed, rather than discreet stable
populations, ISCs likely transition between active and
reserve phenotypes to meet the instantaneous needs of
normal or injured epithelium [42]. This plasticity creates
functional capacity to accommodate wide variations in
environmental challenges to the integrity of the mucosa
[43]. In turn, this plasticity requires specific mechanisms
that maintain the quantity and relative balance of active
and reserve stem cells and are only now being discovered.
Here, we reveal that GUCY2C is one key
determinant of the quantity and relative balance of active
and reserve ISCs. In the absence of GUCY2C, there is a
reduction in the quantity of ISCs, reflected in their overall
number and in their ability to form enteroids ex vivo. Also,
there is a shift in the relative balance of these cells with
a decrease in active Lgr5+ cells and a reciprocal increase
in reserve Bmi1+ cells. Regulation of the quantity and

Figure 3: GUCY2C opposes ER stress balancing active and reserve ISCs. (A, B) Quantification of crypt ER stress marker
expression, relative to tubulin, in Gucy2c+/+ and Gucy2c–/– mice (n = 3). (C, D) Grp78 (BiP) expression in crypts (*) of Gucy2c+/+ mice,
and Gucy2c–/– mice before and after treatment with TUDCA or 8Br-cGMP. (E, F) Quantification of crypt Lgr5+GFP+ and Bmi1+ cells in
Gucy2c+/+ and Gucy2c–/– mice following oral TUDCA for 3 d. *p < 0.05; ***p < 0.001; ns, not significant. Bar in C represents 20 µm.
www.impactjournals.com/oncotarget
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relative balance of ISCs is associated with the functional
co-expression of GUCY2C in stem cells. In that context,
reconstitution of cGMP signaling by oral delivery of 8BrcGMP in Gucy2c–/– mice restored the quantity and relative
balance of active and reserve stem cells. Eliminating
GUCY2C is associated with chronic ER stress in crypts,
a process associated with loss of stem cells in intestine
[34, 44]. ER stress may contribute to ISC loss in Gucy2c–/–
mice since 8Br-cGMP or TUDCA, a chemical chaperone
[35], resolved ER stress and restored the quantity and
balance of Lgr5+ and Bmi1+ stem cells. Importantly,
silencing GUCY2C increased ISC vulnerability, stem
cell loss, and epithelial injury and delayed regeneration in
Gucy2c–/– mice exposed to sub-lethal doses of radiation.
These observations highlight a previously unknown role
for GUCY2C in maintaining and balancing pools of active
and reserve stem cells which, in turn, impacts regenerative
epithelial responses to environmental insults.
Mechanisms regulating ISC pools by GUCY2C are
likely complex and multi-factorial. Generally, GUCY2C
effects are mediated by luminocentric paracrine and
autocrine signaling driven by the hormones guanylin and
uroguanylin [19]. In ISCs, this regulation may be mediated
selectively by guanylin, whose mRNA is expressed in
intestinal crypts [45]. The effects of hormone signaling
may be cell-autonomous, mediated directly by ISCs,
which express GUCY2C in apical membranes making
them accessible to luminocentric hormone secretion.
Alternatively, these effects may be non-autonomous
reflecting the essential role of Paneth cells in maintaining
ISCs [2, 8, 23, 36] and the loss of those cells when
GUCY2C is silenced [14]. Also, loss of ISCs in the
absence of GUCY2C may reflect the associated ER stress,

which exits stem cells out of the active Lgr5+ pool and into
the proliferating progenitor (transit amplifying) pool as
part of the canonical differentiation program that renews
the intestinal epithelium [34]. Indeed, these observations
provide one mechanistic explanation for expansion of the
proliferating progenitor cell compartment in intestinal
crypts in Gucy2c–/– mice [13–15, 20, 29]. Further, loss of
ISCs in the absence of GUCY2C may reflect an increase
in stem cell vulnerability to environmental insults, again
likely reflecting the associated chronic ER stress which
amplifies stem cell susceptibility to apoptosis [44]. In
that regard, GUCY2C signaling enhances resistance of
intestinal epithelial cells to chemical, inflammatory and
radiation-induced injury [14, 18, 21, 46-48]. Moreover,
here we reveal that active Lgr5+ cells and reserve Bmi1+
cells, which are typically resistant to insults [6], are
sensitized to radiation injury in the absence of GUCY2C
signaling. Beyond exiting stem cells from the ISC pool
and amplifying their vulnerability, the impact of GUCY2C
signaling on the plasticity of ISCs and their ability to shift
between active and reserve pools remains to be defined.
In that context, while there is a reciprocal increase in the
reserve Bmi1+ cell pool in Gucy2c–/– mice, these cells fail
to fully compensate for the loss of, or restore, active Lgr5+
cells in the normal or irradiated epithelium, respectively.
These observations suggest that GUCY2C signaling may
play a role in the interconversion of Bmi1+ and Lgr5+ cells
that, in part, defines the functional capacity to regenerate
in response to environmental insults.
Based on the present observations, it is tempting
to speculate that the role of GUCY2C signaling in
pathophysiological mechanisms reflects, at least in part,
a contribution of dysregulation of the ISC compartment.

Figure 4: Maintenance of ISCs by GUCY2C contributes to regenerative responses following radiation-induced intestinal
injury. Lgr5-EGFP-Cre-Gucy2c+/+ and –Gucy2c–/– mice received 10 Gy of irradiation and the dynamics of (A–B) viable crypts, (C) GFP+Lgr5+
active stem cells, and (D) Bmi1+ reserve stem cells were quantified over the subsequent 3 days. Bar in B represents 100 µm.
www.impactjournals.com/oncotarget
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The GUCY2C signaling axis is universally silenced in
colorectal cancer reflecting loss of expression of guanylin
in transforming crypts [49-51]. Conversely, eliminating
GUCY2C expression promotes intestinal tumorigenesis
[14, 20, 52]. The current pathophysiological paradigm of
intestinal cancer suggests that initiating transformational
events occur in the stem cell compartment [53]. Further,
Bmi1 has been identified as an important transcription
factor supporting the transformation of cancer stem cells
in a variety of tumors [54, 55]. Moreover, GUCY2C is a
key component of mechanisms regulating DNA damage
repair [14]. These observations suggest a hypothesis in
which loss of guanylin silences GUCY2C, shifting ISC
pools from active Lgr5+ cells to Bmi1+ cells which, in
the absence of cGMP signaling, may be particularly
vulnerable to genotoxic insults amplifying the risk of
transformation and cancer. Similarly, inflammatory bowel
disease (IBD) is associated with a loss of components of
the GUCY2C signaling axis [56]. Conversely, eliminating
GUCY2C signaling amplifies tissue injury and mortality in
rodent models of IBD [18, 21, 47, 48]. These data suggest
a hypothesis in which the loss of GUCY2C signaling in
IBD changes the quantity, balance, and quality of stem
cells which, in turn, contributes to their vulnerability to
injury and attenuates regenerative responses restoring
the damaged epithelium. These considerations suggest
previously unanticipated pathophysiological paradigms
underlying colorectal cancer and IBD which can be
explored in future studies.
Beyond pathophysiology, these observations suggest
correlative translational opportunities to develop novel
therapeutic and preventive approaches that target ISCs.
In that context, there are several oral GUCY2C ligands
approved, or in development, to treat chronic constipation
syndromes [57]. Lumenal expression of GUCY2C by stem
cells highlights the feasibility of targeting this receptor
using oral replacement strategies to correct paracrine
hormone insufficiencies creating dysfunction in the
ISC compartment. Indeed, here the FDA-approved oral
GUCY2C ligand linaclotide (Linzess™) amplified the
enteroid-forming capacity, a measure of stem cell quantity
and quality, in wild type mice (see Figure 2H). Further,
lumenal GUCY2C ligand replacement attenuates intestinal
tumorigenesis in mice, and oral GUCY2C ligands are
being examined as a novel chemoprevention strategy for
colorectal cancer in humans [52, 58, 59]. Additionally,
lumenal replacement of GUCY2C ligands ameliorates
inflammation in mice, and these agents are in early
clinical development in IBD patients [21, 60]. Moreover,
the present study reveals that silencing the GUCY2C
axis exacerbates the radiation-induced gastrointestinal
syndrome (RIGS), the pathophysiology of which has been
largely attributed to damage and death of ISCs [61, 62]. The
present observations underscore the potential for therapeutic
targeting of this signaling axis using oral GUCY2C ligands
to defend the crypt to attenuate or prevent RIGS.
www.impactjournals.com/oncotarget

In conclusion, we demonstrate that the guanylate
cyclase C (GUCY2C) paracrine signaling axis, a key
regulator of intestinal epithelial homeostasis, maintains the
integrity and balance of active and reserve intestinal stem
cells by modulating endoplasmic reticulum stress. These
studies reveal a novel role for GUCY2C in supporting
intestinal stem cells. Importantly, they underscore the
therapeutic potential of oral GUCY2C ligands to prevent
or treat diseases reflecting intestinal stem cell dysfunction,
including the radiation-induced gastrointestinal syndrome.

MATERIALS AND METHODS
Mice and treatments
Gucyc–/– (Gucy2ctm1Gar [63]),
Lgr5-EGFPCreERT2 (B6.129P2-Lgr5tm1(cre/ERT2)Cle/J; Jax, Bar Harbor,
ME, #008875) and Rosa-STOPfl-LacZ (B6.129S4Gt(ROSA)26Sortm1Sor/J; Jax #003474) transgenic mouse
lines were interbred to generate offspring with the desired
alleles. All mice were co-housed and Gucy2c+/+ (wild
type) littermates with the appropriate alleles were used as
controls. Tissues were harvested from adult mice (12-16
wk of age). Cre was induced with a single 200 μL dose
of tamoxifen (Sigma; Billerica, MA; T5648) in sunflower
oil at 10 mg/ml. Tauroursodeoxycholic Acid (TUDCA,
Millipore 580549) treatments were administered daily for
3 d at 100 mg/kg/day intraperitoneally. Mice were exposed
to a single 10 Gy dose of whole-body γ-irradiation with a
PanTak, 310 kVe x-ray machine and tissues were harvested
at noted time points after irradiation. In some experiments,
mice were gavaged daily for 7 d with 100 μL of 20 mM
8-cpt-cGMP. Each point in a graph (n) represents one
mouse unless otherwise noted. All animal protocols were
approved by the Thomas Jefferson University Institutional
Animal Care and Use committee.

Immunohistochemistry and immunofluorescence
Intestines were harvested from mice, fixed in
formalin, and embedded in paraffin as previously
described [20]. Sections (4 μM) were cut then rehydrated
in a sequential ethanol-to-water bath and stained with
hematoxylin and eosin or antigen-specific primary
and secondary antibodies. Primary antibodies for
immunofluorescence included: anti-GFP, anti-Bmi1, and
anti-GRP78 (Abcam; Cambridge, MA); anti-phospho
VASP Ser239 (Sigma; Billerica, MA); and anti-GUCY2C
(prepared and validated in-house) [64]. Secondary
antibodies were from Life Technologies (Waltham,
MA) and specific to the primary hosts. Tyramide signal
amplification [65] was used to detect GUCY2C; secondary
antibodies conjugated to horseradish peroxidase were from
Jackson Immunoresearch Laboratories (cat #115-035206 and #111-036-046, 1:1000 dilution), and fluoresceinconjugated tyramine was prepared from tyramine HCl
102929
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(cat #T2879, Sigma) and NHS-fluorescein (cat #46410,
Thermo Scientific) as described [66]. For visualization of
Rosa-LacZ lineage tracing, tamoxifen-induced recombinant
Cre intestines were prepared as described previously [67].
At least 4 intestinal circumference sections were evaluated
per mouse.

(Epicentre, Madison, WI) and then subjected to one-step
reverse transcription polymerase chain reaction using
TaqMan EZ reverse-transcription polymerase chain
reaction Core Reagents and appropriate primer/probes for
TaqMan GeneExpression Assays in an ABI 7900 (Applied
Biosystems, Norwalk, CT).

Crypt isolation and culture

Immunoblot

Crypt isolation for subsequent analyses (enteroid
assay, florescence-activated cell sorting (FACS),
immunoblot) was performed using a variation of the
chelation dissociation method [68]. Briefly, intestines
were harvested, villi were gently scraped off for the
small intestine, and tissues were minced and incubated
in a 10 mM EDTA/Ca-free, Mg-free Hank’s Balanced
Salt Solution (HBSS) on ice for a total of 40 min.
Throughout this time, solutions were intermittently
shaken by hand at the speed of two shakes/second,
supernatant was disposed a total of six times, and fresh
EDTA/HBSS was added after each disposal. Tissue
was incubated undisturbed for 30 min on ice followed
by vigorous pipetting with a 10 mL pipet to dissociate
the remaining crypts. Crypts were filtered through a
70 µM strainer and pelleted. For enteroid culture, the
same number of crypts for each genotype (ranging from
300–1500 crypts/well) were resuspended in a matrigel
droplet (BD, 354230), pipetted briefly with a 1000
μL micropipette, plated in 30 μL, and overlaid with
350 μL of Intesticult media (Stem Cell Technologies,
Vancouver, Canada; 06005). For FACS, crypts were
incubated in 0.25% trypsin (Thermo Scientific,
Philadelphia, PA; 15050065) at 37°C until a single cell
suspension was obtained (not more than 10 min). Cells
were then filtered a second time using a 40 µM strainer
and kept in EDTA solution for sorting.

Protein was extracted as described [52], quantitated
using BCA assay (Pierce) and subjected to immunoblot
analysis using anti-Bmi1 (Abcam; Cambridge, MA), antiCHOP, anti-calreticulin, anti-phospho-EIF2α, anti-β-tubulin
(Cell Signaling, Danvers, MA) and anti-Grp78 (Abcam).
Secondary antibodies were from Santa Cruz Biotechnology
(Dallas, TX). Molecular weight markers (Cat. # 10748010,
5 µL per run, or Cat. #LC5800, 10 µL per run) for
immunoblot analyses were from Invitrogen (Grand
Island, NY).

Fluorescence-activated cell sorting

Statistical analyses

Cell populations from Lgr5-EGFP-CreERT2 mice
were collected using a Coulter MoFlo Cell Sorter or
analyzed using a BD LSRII. Live cells, determined by
forward scatter, side scatter, and propidium iodide (PI,
Roche), were gated negatively on CD45 (BD Pharmingen,
San Jose, CA), then positively gated on CD24Low (BD
Pharmingen) [69, 70]. Finally, cells were gated negatively
(for differentiated cells) and positively (for Lgr5+ cells)
gated on endogenous eGFP fluorescence (Supplementary
Figure 1).

All analyses were conducted in a blinded fashion.
Two-tailed student’s t-tests were used for single
comparisons, and two-way analysis of variance (ANOVA)
for multiple comparisons, unless otherwise indicated.
Cohort sizes were calculated to be sufficient to detect
two-tailed statistically significant differences with 95%
confidence and 80% power, assuming unequal variances
and allowing for unequal sample sizes between groups.
P < 0.05 was considered significant. Statistical analyses
were performed with GraphPad Prism 6 software. Data
represent mean ± SEM.

Transmission electron microscopy
Pieces (3 cm) of intestinal tissue were placed in
fixative containing 2.5% glutaraldehyde, 0.1% tannic
acid, and 0.1 mol/L phosphate buffer for 5 min three times
and stored at 4°C. Tissues were mounted in plastic blocks,
processed through 0.1 mol/L phosphate buffer supplied
with 2% OsO4 (Osmium), uranyl acetate, then dehydrated
through a graded acetone sequence. After being embedded
in Spurrs media, blocks were sectioned and visualized
using a FEI Tecnai 12 microscope and images will be
captured with an AMT digital camera. Representative
electron micrographs of each group were taken (kindly
performed by Timothy Schneider, Department of
Pathology, Thomas Jefferson University). Cells from at
least 30 crypts were enumerated per mouse.

Quantitative reverse transcriptase-polymerase
chain reaction (RT-qPCR)

Abbreviations

RNA from sorted cells was amplified and reverse
transcribed in situ using total RNA from the CD45–/
CD24Low/EGFP+ population. RNA was amplified using
MessageBOOSTER cDNA Synthesis Kit for qPCR
www.impactjournals.com/oncotarget

CBC, crypt base columnar; cGMP, cyclic GMP; ER,
endoplasmic reticulum; GUCY2C, guanylyl cyclase C;
ISC, intestinal stem cells; ST, bacterial heat-stable
enterotoxin.
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